3 Results for "

bone+damage

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "bone+damage" in MCE Product Catalog:

ML191
ML191
0 Images
Cat. No.: HY-111083
CAS No.: 931695-79-3
Purity:  99.65%
Synonyms: CID23612552
Target:  

GPR55 PERK PKC ERK p38 MAPK

Research Areas:  

Metabolic Disease Cancer

ML191 (CID23612552) is a GPR55 antagonist. ML191 inhibits ERK phosphorylation and PKC β II translocation downstream of GPR55 signaling. ML191 suppresses LPI-induced activation of ERK1/2 and p38 MAPK signaling, blocks the transcription of RANKL-induced osteoclastogenesis markers, and reduces the bone resorption activity of mature osteoclasts promoted by RANKL. ML191 can be used to investigate diseases associated with bone degradation caused by excessive osteoclast activation, such as osteoporosis and bone damage during the formation stage of bone metastases .
LY221068
LY221068
0 Images
Cat. No.: HY-114565
CAS No.: 132392-39-3
Target:  

Lipoxygenase Enterovirus

Research Areas:  

Inflammation/Immunology

LY221068 is an anti-oxidant and an orally active, potent inhibitor of iron-dependent lipid peroxidation and 5-lipoxygenase with antiinflammatory properties. LY221068 inhibits bone damage and paw swelling in the Freund's Complete adjuvant (HY-153808) induced arthritis (FCA) model of rats. LY221068 is promising for research of arthritis .
LY256548
LY256548
0 Images
Cat. No.: HY-114873
CAS No.: 107889-31-6
Synonyms: LY25684
Target:  

Phospholipase COX Lipoxygenase Leukotriene Receptor

Research Areas:  

Inflammation/Immunology

LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model .
Assay Types